MEI Pharma, Inc., an oncology company, has announced the retirement of the company's chairman Bryan Williams.
Effective upon Professor Williams' retirement, Christine A. White, will serve as Lead Director until a new Chairman has been appointed. Professor Williams has been a member of the Board since March 2006 and has served as Chairman since November 2006.
"It has been a pleasure and a great honor to have served with Bryan," said Daniel P. Gold, Ph.D., President and CEO of MEI Pharma. "Bryan's leadership on the board was critical during the Company's transition from R&D to clinical development and he has been a source of strength for our Board over the course of the past seven years.
"On behalf of all of us, I would like to thank him for the significant contributions he has made to the Company. I am confident that we will find a qualified and proven successor as Chairman to help us continue in the strategic direction that Bryan helped to put in place."
Dr White was appointed as a director in August 2010. She was with Biogen Idec from 1996 to 2005, most recently as Senior vice president, Global Medical Affairs, where she played an integral role in the clinical development, regulatory affairs and commercialization of oncology drugs Rituxan and Zevalin. Dr White also serves as a member of the board of directors of Arena Pharmaceuticals.